Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

The research has generated significant interest from firms in food & supplements as consumers seek natural alternatives to GLP-1 drugs.

A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and disease prevention.

Myosteatosis is associated with poor outcomes in various liver diseases. However, standardized methods for assessing, defining, and diagnosing myosteatosis in the context of liver diseases remain ...

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of ...

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes ...

What happens when this doctor goes keto and his LDL rockets to 574? We dive deep into the science, controversy, and personal decision-making behind the most misunderstood lipid profile in cardiology.

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro to lose weight.

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

If you’re looking to create a healthier lifestyle, look no further than the power of running. Movement makes up a portion of the weight loss puzzle, and with our new Running for Weight Loss program, ...